Advertisement

Related Videos

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Oct
15
Today In Oncology
Should Lung Cancer Screening Guidelines Be Expanded to Include Female Asian Nonsmokers?
FDA Approves Combination Regimen for Extensive-Stage SCLC
Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated Advanced NSCLC
In Extensive-Stage Small Cell Lung Cancer Novel Maintenance Regimen Boosts Overall Survival
Fertility-Sparing Surgery vs Hysterectomy for Early-Stage Cervical Cancer: Comparable Survival Rates but Higher Recurrence Risk
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo